

## ***Practical Guide to Pharmacoeconomics***

### **Correction**

On page 69, please note the following correction:

#### **PenUltimate**

You are watching a presentation from a marketing representative for Initech Solutions drug company. The representative has come to Healthside Hospital to give information about a new carbapenem called PenUltimate. PenUltimate has been shown in tests to cure multidrug-resistant (MDR) Escherichia coli infections **85%** of the time. It costs \$275 for a 10-day treatment and has a side effect rate of 15%.